Evidence map›Paper›PMID 40186871›Full record

ArticleCell reports2025

The Chlamydia effector Dre1 binds dynactin to reposition host organelles during infection.

Jessica Sherry, Komal Ishwar Pawar, Lee Dolat, Erin Smith, I-Chang Chang, Khavong Pha, Robyn Kaake, Danielle L Swaney, Clara Herrera, Eleanor McMahon and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Inclusion Membrane Proteins ofMicroorganisms · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jessica SherryDepartment of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
Komal Ishwar PawarDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94143, USA.
Lee DolatDepartment of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA.
Erin SmithDepartment of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA.
I-Chang ChangDepartment of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA.
Khavong PhaDepartment of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
Robyn KaakeDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94143, USA.
Danielle L SwaneyDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94143, USA.
Clara HerreraDepartment of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
Eleanor McMahonDepartment of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
Robert J BastidasDepartment of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA.
Jeffrey R JohnsonDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94143, USA.
Raphael H ValdiviaDepartment of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA.
Nevan J KroganDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94143, USA.
Cherilyn A ElwellDepartment of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA. Electronic address: cherilyn.elwell@ucsf.edu.
Kliment VerbaDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94143, USA. Electronic address: kliment.verba@ucsf.edu.
Joanne N EngelDepartment of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA. Electronic address: jengel@medicine.ucsf.edu.

Funding

Microbial Pathogenesis and Host DefenseT32AI060537 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joanne N. Engel · 2004 to 2026
$6.5M
Novel approaches to identify host genes required for Chlamydia pathogenesisR01AI073770 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ENGEL, JOANNE N. · 2007 to 2016
$3.8M
Decoding the Chlamydia inclusion membrane protein-host protein interactomeR01AI122747 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ENGEL, JOANNE N., KAAKE, ROBYN MIDORI · 2016 to 2020
$3.1M
Functional characterization of early Chlamydia effectorsR01AI134891 · NIAID · DUKE UNIVERSITY · PI VALDIVIA, RAPHAEL H · 2018 to 2022
$2.4M
Glacios™ Cryo Transmission Electron Microscope with 200 kV XFEG opticsS10OD026881 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHENG, YIFAN · 2019 to 2019
$1.8M
Inclusion membrane protein (Inc) modulation of the innate immune response to Chlamydia trachomatisR56AI152526 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ENGEL, JOANNE N., SWANEY, DANIELLE L · 2020 to 2020
$803k
High throughput proteomics to dissect Chlamydia-host cell interactionsR21AI105561 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ENGEL, JOANNE N. · 2013 to 2014
$419k
Subversion of the host cell cytoskeleton and innate immunity by Chlamydia trachomatisF32AI138372 · NIAID · DUKE UNIVERSITY · PI DOLAT, LEE · 2019 to 2021
$235k
Remodeling of the Host Ubiquitin Landscape by Chlamydia trachomatisF32AI133902 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PHA, KHAVONG · 2017 to 2019
$179k
Decoding the interaction of the Chlamydia secreted effector CT192 with host dynactinF31AI133951 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHERRY, JESSICA · 2017 to 2019
$117k
NIAID NIH HHS F31 AI133951NIAID NIH HHS F32 AI133902NIAID NIH HHS F32 AI138372NIAID NIH HHS R01 AI073770NIAID NIH HHS R01 AI122747NIAID NIH HHS R01 AI134891NIAID NIH HHS R21 AI105561NIAID NIH HHS R56 AI152526NIAID NIH HHS T32 AI060537NIH HHS S10 OD026881
6 · The paper itself

Abstract

The obligate intracellular pathogen Chlamydia trachomatis replicates in a specialized membrane-bound compartment where it repositions host organelles during infection to acquire nutrients and evade host surveillance. We describe a bacterial effector, Dre1, that binds specifically to dynactin associated with host microtubule organizing centers without globally impeding dynactin function. Dre1 is required to reposition the centrosome, mitotic spindle, Golgi apparatus, and primary cilia around the inclusion and contributes to pathogen fitness in cell-based and mouse models of infection. We utilized Dre1 to affinity purify the megadalton dynactin protein complex and determined the first cryoelectron microscopy (cryo-EM) structure of human dynactin. Our results suggest that Dre1 binds to the pointed end of dynactin and uncovers the first bacterial effector that modulates dynactin function. Our work highlights how a pathogen employs a single effector to evoke targeted, large-scale changes in host cell organization that facilitate pathogen growth without inhibiting host viability.

Indexed as

Bacterial ProteinsChlamydia InfectionsChlamydia trachomatisDynactin ComplexOrganellesAnimalsCryoelectron MicroscopyHeLa CellsHost-Pathogen InteractionsHumansMiceProtein BindingBacterial ProteinsDynactin Complexbacterial pathogenesiscentrosomeChlamydiaCP: Cell biologyCP: MicrobiologydynactinGolgi apparatushost-pathogen interactionsmicrotubule organizing centerprimary cilia

Identifiers

PMID40186871
PMCPMC12139634

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.